Company intelligence / Profile preview

Crysalis Biosciences

Sauget, Illinois, United Statescrysalisbio.com ↗

Ownership: Private
Employees: ~34
Development stage: Commercial

Overview

Crysalis has completed the acquisition and retrofit of the Monarch facility in Sauget, Illinois—a former ethanol plant—now upgraded to produce up to 55 million gallons per year of low-carbon intensity sustainable aviation fuel (SAF) and feedstocks. The plant has received environmental authorization under new Illinois EPA standards. The company recently secured major investment from Airbus via the SAFFA Fund I, LP. It is also collaborating with Nitto Denko Corporation to develop the world’s first bio-based acetonitrile manufacturing plant.

Industry: Non-Drug Biotech

Partnerships

Nitto Denko CorporationAirbus/Sustainable Aviation Fuel Financing Alliance Fund I, LP ("SAFFA Fund")

Beyond the preview

Go deeper on Crysalis Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crysalis Biosciences.

Explore the full profile